Section Arrow
TYRA.NASDAQ
- Tyra Biosciences
Quotes are at least 15-min delayed:2026/01/05 07:20 EST
Pre Market
Last
 26.79
0 (0.00%)
Bid
24.7
Ask
29.7
High 26.79 
Low 26.79 
Volume 29 
Regular Hours (Closed)
Last
 26.79
+0.5 (+1.90%)
Day High 
27.66 
Prev. Close
26.29 
1-M High
26.41 
Volume 
793.78K 
Bid
24.7
Ask
29.7
Day Low
25.9875 
Open
26.28 
1-M Low
20.075 
Market Cap 
1.39B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 25.15 
20-SMA 23.73 
50-SMA 19.58 
52-W High 26.41 
52-W Low 6.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.88/-2.71
Enterprise Value
1.40B
Balance Sheet
Book Value Per Share
5.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6991 +0.0391 +5.92%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5413 +0.0309 +6.05%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.71 +0.36 +8.28%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.1438 +0.0069 +5.04%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.